CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 9 enrolled
Drug / intervention
NavDxother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05814549
NCT05814549N/AActive
CompareCT.gov

A Study of Using Plasma Circulating Cell Free Human Papillomavirus Deoxyribonucleic Acid to Screen (cf HPV DNA) for HPV-Related Oropharyngeal Cancer

Memorial Sloan Kettering Cancer Center·observational·Posted Apr 18, 2023·Updated Sep 19, 2025

In Brief

An observational study evaluating NavDx for Oropharyngeal Cancer and 2 related conditions. Active but no longer recruiting, targeting 9 participants across 7 sites.

Detailed Summary

The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream. The purpose of this study is to find out whether using this blood test to test for HPV DNA will help detect HPV-related Oropharyngeal Cancer/OPC.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/AActive
20242025202620272028202920302031
First PostedApr 18, 2023
Enrollment StartMar 31, 2023
Primary CompletionMar 31, 2031
TodayJul 1, 2026
Enrollment to primary: 8 yearsPosted 3.2 years agoPrimary completion in 4.8 years

Interventions

NavDxother

Evaluation of HPV presence via NavDx (v1) at two (or three) timepoints o If one of the two blood samples is positive, the subject will have a third NavDx (v1) test approximately 1 month after the second timepoint. If the test is positive, the subject will move to surveillance phase.